Clinical trials group Icon, which is listed on the Dublin and Nasdaq stock markets, has been awarded in excess of $45 million (€52.8 million) in net new business for the fourth quarter ended May 31st, 2001.
The company has estimated that it has already booked 80 per cent of forecast revenues for the financial year ended May 31st, 2002.
Join The Irish Times on WhatsApp and stay up to date
Sign up to the Business Today newsletter for the latest new and commentary in your inbox
Listen to Inside Business podcast for a look at business and economics from an Irish perspective
Get the latest business news and commentary from our expert business team in your inbox every weekday morning
